Physician profile
Sameh Youssef
NPI 1225036304
$11,388.14
in general payments reported to CMS, 2019-2025
33 companies · $1,879 in 2025
The $1,879 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $991 · 2020: $1,146 · 2021: $1,937 · 2022: $1,841 · 2023: $1,446 · 2024: $2,147 · 2025: $1,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,472.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,311.00 | 2019-2025 | Aveir, Jot Dx |
| Amgen INC. | $1,304.88 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,292.61 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $1,261.71 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,095.87 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $801.29 | 2019-2024 | Brilinta, Farxiga |
| Merck Sharp & Dohme LLC | $580.38 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $386.35 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $349.42 | 2021-2025 | Camzyos, Eliquis |
| Atricure, INC. | $346.19 | 2023-2025 | Synergy Ablation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.77 | 2020-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $301.77 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $266.96 | 2023-2025 | Onpattro, Amvuttra |
| Silk Road Medical, INC. | $186.86 | 2022 | |
| Novo Nordisk INC | $181.06 | 2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $169.20 | 2022-2025 | Zepbound, Jardiance |
| Boston Scientific Corporation | $167.89 | 2019-2023 | Lux-Dx Insertable Cardiac Monitor |
| Cvrx, INC. | $167.25 | 2023-2024 | Barostim Neo System |
| Amarin Pharma, INC. | $146.32 | 2020-2021 | |
| Shockwave Medical, INC | $140.40 | 2022 | |
| Biosense Webster, INC. | $138.83 | 2024 | Carto 3 |
| Medtronic, INC. | $130.12 | 2021-2024 | Closurefast, Reveal Linq |
| Bolton Medical INC | $52.08 | 2025 | Relay Thoracic Stent-Graft With Plus Delivery System |
| Braemar Manufacturing, LLC | $42.47 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $39.39 | 2024 | Evkeeza |
| Kestra Medical Technology Services, INC. | $26.29 | 2023 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.63 | 2023 | Lifevest |
| Tris Pharma INC | $25.21 | 2025 | Dyanavel Xr |
| Lexicon Pharmaceuticals, INC. | $24.90 | 2024 | |
| Becton, Dickinson and Company | $24.04 | 2024 | Venclose Maven Catheter |
| Medicure Pharma INC. | $21.37 | 2021 | |
| Vital Connect, INC | $19.86 | 2025 | Vitalpatch Rtm |
| Exact Sciences Corporation | $19.77 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameh Youssef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.